Company Overview and News

 
KLCI stages technical rebound, reverses earlier loss

2018-10-12 theedgemarkets
KUALA LUMPUR (Oct 12): The FBM KLCI staged a technical rebound today to snap its losing streak and rose 0.54% at mid-morning, reversing its earlier loss, lifted by index heavyweights Malayan Banking Bhd (Maybank) and Tenaga Nasional Bhd.
MLYBY MLYNF UPBMF 7036 BATS 4162 3034 2089 5014 9334 5199 2852 1155 5347 3301 3867 TNABY MYPRY 2836 TNABF HIPEF GEBHF

 
KLCI remains marginally lower, construction stocks fall

2018-10-08 theedgemarkets
KUALA LUMPUR (Oct 8): The FBM KLCI remained marginally in the negative zone, having pared much of its losses in the morning session today, against the backdrop of weaker regional markets.
SPMXF 7036 5681 5263 BATS 4162 1163 5256 7123 5199 SPMXY 5225 3026 3301 3867 1899 Q0F IHHHF HIPEF GEBHF

 
KLCI pares loss, remains in red tracking regional markets

2018-10-08 theedgemarkets
KUALA LUMPUR (Oct 8): The FBM KLCI pared some of its loss at mid-morning today, but remained in the negative zone in line with its key regional peers.
HLFBF SPMXF UPBMF 7036 1082 7113 TPGVF BATS 4162 7087 2089 9334 7123 TGLVY SPMXY 5225 3026 3301 0026 1899 Q0F IHHHF GEBHF

 
KLCI falls 0.38% in tandem with regional retreat

2018-10-05 theedgemarkets
KUALA LUMPUR (Oct 5): The FBM KLCI fell 0.38% at mid-morning today, tracking fragile regional markets.
UPBMF 7113 TPGVF BATS 4162 2291 5202 2089 9334 6033 9113 4634 TGLVY 5139 PNADF 5226 3301 NDAQ 0900 6888 5819 AXXTF 1902 PNAGF

 
KLCI edges up but stays shy of 1,800 level

2018-10-02 theedgemarkets
KUALA LUMPUR (Oct 2): The FBM KLCI edged up at mid-morning today but stayed shy of the crucial 1,800-point level.
UPBMF BATS 4162 5168 2089 5256 5199 4456 3301 0026 7108 HIPEF 3719 HRGHY

 
FBM KLCI notches limited gains as region stays muted

2018-10-01 theedgemarkets
KUALA LUMPUR (Oct 1): The FBM KLCI notched up limited gains at the midday break today as decliners overtook advancers, against the backdrop of mixed regional markets.
APEXF 7084 7090 BATS 4162 0082 1163 5268 5256 6033 5199 0020 5843 0176 PNADF 1201 3301 7108 1899 2836 HIPEF PNAGF

 
FBM KLCI pares gains, subdued in line with region

2018-10-01 theedgemarkets
KUALA LUMPUR (Oct 1): The FBM KLCI pared some of its gains at mid-morning, keeping the local index subdued in line with the regional markets on the first trading day of the fourth quarter.
APEXF 7090 BATS 4162 2089 5256 9334 5199 5008 5843 1201 3026 3301 3867 2836 HIPEF PNAGF 7084 UPBMF 5681 5268 6033 PNADF 0026 1899

 
KLCI erases earlier loss, crosses 1,800-level

2018-09-27 theedgemarkets
KUALA LUMPUR (Sept 27): The FBM KLCI erased its earlier losses and rose at mid-morning to cross the 1,800-point level.
5072 8621 7158 BATS 4162 7215 2089 5199 5347 3301 7668 TNABY AXXTF HIPEF PNAGF UPBMF 1163 5202 8311 6033 2593 5139 PNADF 0900 6888 TNABF 3719

 
KLCI drifts lower, tracks regional markets

2018-09-25 theedgemarkets
KUALA LUMPUR (Sept 25): The FBM KLCI drifted lower at mid-morning, tracking the lacklustre regional markets.
HLFBF APEXF BRDBF 7090 7181 7036 1082 5681 BATS 4162 1163 5256 5199 5210 4456 3301 0026 7668 HIPEF 3719

 
KLCI up 0.39% in tandem with regional uptrend

2018-09-21 theedgemarkets
KUALA LUMPUR (Sept 21): The FBM KLCI rose 0.39% at midday break Friday, tracking gains at regional markets, as worries over the US-China trade tensions abated somewhat.
7084 7052 GMALF 5681 BATS 4162 5134 7079 GMALY 5139 KLKBY 2445 3301 4715 7216 0900 0026 2836

 
KLCI remains firmly above 1,800-level

2018-09-21 theedgemarkets
KUALA LUMPUR (Sept 21): The FBM KLCI remained firmly above the 1,800-point level at mid-morning and was up 0.37%, tracking the gains at regional markets.
HLFBF 7084 7052 1082 BATS 4162 7374 0089 5139 KLKBY 2445 3301 7216 0900 0026 2836

 
KLCI rises 0.46% as select blue chips lift

2018-09-20 theedgemarkets
KUALA LUMPUR (Sept 20): The FBM KLCI rose 0.46% at mid-morning, tracking gains at the regional markets, lifted by select index-linked blue chips.
HLFBF 7052 GMALF 1082 BATS 4162 0096 5256 5199 GMALY 5139 5258 3301 4715 0900 5208 5819 2836 HIPEF

 
KLCI dips 0.39% as select blue chips drag

2018-09-13 theedgemarkets
KUALA LUMPUR (Sept 13): The FBM KLCI dipped 0.39% at mid-morning, dragged by losses at select index-linked blue chips.
HLFBF PBLOF UPBMF 7036 1082 7113 5681 TPGVF BATS 4162 0096 7087 1295 2089 5256 9334 TGLVY 5139 5258 3301 0900 5819

 
KLCI pares loss, poised to extend lacklustre run

2018-09-05 theedgemarkets
KUALA LUMPUR (Sept 5): The FBM KLCI pared some of its loss at the midday break today, but looked poised to extend its lacklustre start in September.
HLFBF APEXF PBLOF 7090 SPMXF 7036 1082 5681 BATS 4162 0162 1295 8311 6033 5199 PNADF SPMXY 3026 3301 1368 HIPEF PNAGF

 
KLCI poised to close lower for fourth day

2018-09-04 theedgemarkets
KUALA LUMPUR (Sept 4): The FBM KLCI looked poised to close lower for the fourth consecutive day and maintain its poor start to September at midday break today, tracking losses at regional markets.
UPBMF 7113 TPGVF BATS 4162 5168 2089 8311 7123 5199 7079 3522 TGLVY 3026 3301 3867 6888 5819 AXXTF 2836 HIPEF HRGHY

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...